| Options Wellness Center, Llc | |
|
1005 Avalon Ave Muscle Shoals AL 35661-2401 | |
| (256) 978-5740 | |
| (256) 978-5774 |
| Full Name | Options Wellness Center, Llc |
|---|---|
| Speciality | Clinic/Center |
| Location | 1005 Avalon Ave, Muscle Shoals, Alabama |
| Authorized Official Name and Position | Susan Warren Bentley (PROVIDER/OWNER) |
| Authorized Official Contact | 2569785740 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Options Wellness Center, Llc 1005 Avalon Ave Muscle Shoals AL 35661-2401 Ph: (256) 978-5740 | Options Wellness Center, Llc 1005 Avalon Ave Muscle Shoals AL 35661-2401 Ph: (256) 978-5740 |
| NPI Number | 1063987113 |
|---|---|
| Provider Enumeration Date | 10/04/2018 |
| Last Update Date | 12/17/2019 |
| Medicare PECOS PAC ID | 8224460092 |
|---|---|
| Medicare Enrollment ID | O20191115002027 |
News Archive
OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has received a letter from NASDAQ Global Market exchange confirming that, with the appointment of Tamar Howson to the Company's audit committee, as detailed in the Company's Form 8-K filed on April 5, 2010, NASDAQ staff has determined that the Company complies with Listing Rule 5605(c)(2)
A new primate study published in the journal Nature in January 2020, reports that the almost century-old BCG vaccine against tuberculosis, may be used differently to achieve better protection against lung tuberculosis. While more work remains to be carried out before the findings can be accepted as the basis for clinical practice, they are extremely promising in the fight against this killer.
Accuray Incorporated, a global leader in the field of radiosurgery, announced today it received Shonin approval from the Japanese Ministry of Health, Labor and Welfare to market the CyberKnife G4 Robotic Radiosurgery System to treat tumors non-invasively anywhere in the body, inclusive of head and neck. The System will be marketed in Japan as the "CyberKnife Radiosurgery System."
Actelion Pharmaceuticals US, Inc., today announced the first commercial sales of a new 20 microgram per milliliter (mcg/mL) formulation of Ventavis(R), for the treatment of New York Heart Association Class III and IV pulmonary arterial hypertension (PAH). This increased strength formulation delivers the same dose of Ventavis in half the volume, which is expected to reduce inhalation time and further support patient compliance.
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063987113 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261Q00000X | Clinic/center | (* (Not Available)) | Primary |
| Provider Name | Filomeno C Gapultos |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1700995065 PECOS PAC ID: 2466431606 Enrollment ID: I20040720000431 |
News Archive
OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has received a letter from NASDAQ Global Market exchange confirming that, with the appointment of Tamar Howson to the Company's audit committee, as detailed in the Company's Form 8-K filed on April 5, 2010, NASDAQ staff has determined that the Company complies with Listing Rule 5605(c)(2)
A new primate study published in the journal Nature in January 2020, reports that the almost century-old BCG vaccine against tuberculosis, may be used differently to achieve better protection against lung tuberculosis. While more work remains to be carried out before the findings can be accepted as the basis for clinical practice, they are extremely promising in the fight against this killer.
Accuray Incorporated, a global leader in the field of radiosurgery, announced today it received Shonin approval from the Japanese Ministry of Health, Labor and Welfare to market the CyberKnife G4 Robotic Radiosurgery System to treat tumors non-invasively anywhere in the body, inclusive of head and neck. The System will be marketed in Japan as the "CyberKnife Radiosurgery System."
Actelion Pharmaceuticals US, Inc., today announced the first commercial sales of a new 20 microgram per milliliter (mcg/mL) formulation of Ventavis(R), for the treatment of New York Heart Association Class III and IV pulmonary arterial hypertension (PAH). This increased strength formulation delivers the same dose of Ventavis in half the volume, which is expected to reduce inhalation time and further support patient compliance.
› Verified 3 days ago
| Provider Name | Susan W Bentley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1194702969 PECOS PAC ID: 9032189568 Enrollment ID: I20070606000315 |
News Archive
OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has received a letter from NASDAQ Global Market exchange confirming that, with the appointment of Tamar Howson to the Company's audit committee, as detailed in the Company's Form 8-K filed on April 5, 2010, NASDAQ staff has determined that the Company complies with Listing Rule 5605(c)(2)
A new primate study published in the journal Nature in January 2020, reports that the almost century-old BCG vaccine against tuberculosis, may be used differently to achieve better protection against lung tuberculosis. While more work remains to be carried out before the findings can be accepted as the basis for clinical practice, they are extremely promising in the fight against this killer.
Accuray Incorporated, a global leader in the field of radiosurgery, announced today it received Shonin approval from the Japanese Ministry of Health, Labor and Welfare to market the CyberKnife G4 Robotic Radiosurgery System to treat tumors non-invasively anywhere in the body, inclusive of head and neck. The System will be marketed in Japan as the "CyberKnife Radiosurgery System."
Actelion Pharmaceuticals US, Inc., today announced the first commercial sales of a new 20 microgram per milliliter (mcg/mL) formulation of Ventavis(R), for the treatment of New York Heart Association Class III and IV pulmonary arterial hypertension (PAH). This increased strength formulation delivers the same dose of Ventavis in half the volume, which is expected to reduce inhalation time and further support patient compliance.
› Verified 3 days ago
News Archive
OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has received a letter from NASDAQ Global Market exchange confirming that, with the appointment of Tamar Howson to the Company's audit committee, as detailed in the Company's Form 8-K filed on April 5, 2010, NASDAQ staff has determined that the Company complies with Listing Rule 5605(c)(2)
A new primate study published in the journal Nature in January 2020, reports that the almost century-old BCG vaccine against tuberculosis, may be used differently to achieve better protection against lung tuberculosis. While more work remains to be carried out before the findings can be accepted as the basis for clinical practice, they are extremely promising in the fight against this killer.
Accuray Incorporated, a global leader in the field of radiosurgery, announced today it received Shonin approval from the Japanese Ministry of Health, Labor and Welfare to market the CyberKnife G4 Robotic Radiosurgery System to treat tumors non-invasively anywhere in the body, inclusive of head and neck. The System will be marketed in Japan as the "CyberKnife Radiosurgery System."
Actelion Pharmaceuticals US, Inc., today announced the first commercial sales of a new 20 microgram per milliliter (mcg/mL) formulation of Ventavis(R), for the treatment of New York Heart Association Class III and IV pulmonary arterial hypertension (PAH). This increased strength formulation delivers the same dose of Ventavis in half the volume, which is expected to reduce inhalation time and further support patient compliance.
› Verified 3 days ago
Family Health Care Clinic, Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 102 Physicians Dr, Suite B, Muscle Shoals, AL 35661 Phone: 601-825-7280 Fax: 601-825-8130 | |
Shoals Hospital - Crna Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 201 Avalon Ave, Muscle Shoals, AL 35661 Phone: 256-768-9191 Fax: 256-768-9775 | |
Shoals Health Group Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 203 Avalon Ave, Muscle Shoals, AL 35661 Phone: 256-718-4041 | |
Dr. Terry J. True Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 104a Physicians Dr, Muscle Shoals, AL 35661 Phone: 256-383-6070 Fax: 256-381-4022 | |
Red Bay Hospital Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 14490 County Line Road, Suite A, Muscle Shoals, AL 35661 Phone: 256-661-2078 | |
Shoals Hospital - Ekg Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 201 Avalon Ave, Muscle Shoals, AL 35661 Phone: 256-768-9191 Fax: 256-768-9775 |